Announced Thu, 7 May · 12:16 IST

Further to the intimation submitted to Stock Exchanges dated May 01, 2026, with respect to the meeting of the Board of Directors of the Company, to be held on Tuesday, May 19, 2026, inter-alia ....

Board & Shareholder Meetings View source PDF

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.5%1-day move
₹621.50
prior close
₹616.15
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.3+0.1+0.1-2.5+0.3-2.6-2.4-0.5+2.0+2.2+0.1+4.7
Up moveDown movePending
AI summary

HCG, India's largest cancer care provider, has informed exchanges that its Board meeting scheduled for May 19, 2026 will consider and approve the Audited Financial Results (Standalone and Consolidated) for Q4 and FY ended March 31, 2026. An earnings conference call is scheduled for the following day, May 20, 2026, at 1:30 PM IST, where senior management will discuss the results and take questions. This is a routine regulatory disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company operates 25 hospitals across India and Africa under the HCG brand, with an additional presence in fertility services under the Milann brand.

Likely market impact

Shareholders and analysts should prepare for the Q4 & FY26 results announcement on May 19, 2026 and the earnings call the next day. This is standard procedural disclosure with no immediate material impact on the stock.